Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies

Luca Antonioli, Sergey V. Novitskiy, Kris F. Sachsenmeier, Matteo Fornai, Corrado Blandizzi, G. Haskó

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Over the past few years, several preclinical studies have highlighted the value of CD73 (ecto-5′-nucleotidase) as a potential therapeutic target for cancer therapy. Indeed, the pharmacological blockade of CD73, via monoclonal antibodies or small molecules, has promise in counteracting cancer development, growth and spread. Synergistic combinations of anti-CD73 drugs with conventional cancer treatments (i.e., chemotherapy, radiation therapy, immunotherapy, targeted therapy) have increased therapeutic potential. In this review, we discuss the potential synergistic effects of CD73 blockers and conventional antineoplastic therapies in the treatment of cancer.

Original languageEnglish
Pages (from-to)1686-1696
Number of pages11
JournalDrug Discovery Today
Volume22
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Antineoplastic Agents
Therapeutics
Neoplasms
5'-Nucleotidase
Growth and Development
Immunotherapy
Radiotherapy
Monoclonal Antibodies
Pharmacology
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Switching off CD73 : a way to boost the activity of conventional and targeted antineoplastic therapies. / Antonioli, Luca; Novitskiy, Sergey V.; Sachsenmeier, Kris F.; Fornai, Matteo; Blandizzi, Corrado; Haskó, G.

In: Drug Discovery Today, Vol. 22, No. 11, 01.11.2017, p. 1686-1696.

Research output: Contribution to journalReview article

Antonioli, Luca ; Novitskiy, Sergey V. ; Sachsenmeier, Kris F. ; Fornai, Matteo ; Blandizzi, Corrado ; Haskó, G. / Switching off CD73 : a way to boost the activity of conventional and targeted antineoplastic therapies. In: Drug Discovery Today. 2017 ; Vol. 22, No. 11. pp. 1686-1696.
@article{a45abd8bba44460a83e0cbda41b42656,
title = "Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies",
abstract = "Over the past few years, several preclinical studies have highlighted the value of CD73 (ecto-5′-nucleotidase) as a potential therapeutic target for cancer therapy. Indeed, the pharmacological blockade of CD73, via monoclonal antibodies or small molecules, has promise in counteracting cancer development, growth and spread. Synergistic combinations of anti-CD73 drugs with conventional cancer treatments (i.e., chemotherapy, radiation therapy, immunotherapy, targeted therapy) have increased therapeutic potential. In this review, we discuss the potential synergistic effects of CD73 blockers and conventional antineoplastic therapies in the treatment of cancer.",
author = "Luca Antonioli and Novitskiy, {Sergey V.} and Sachsenmeier, {Kris F.} and Matteo Fornai and Corrado Blandizzi and G. Hask{\'o}",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.drudis.2017.06.005",
language = "English",
volume = "22",
pages = "1686--1696",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Switching off CD73

T2 - a way to boost the activity of conventional and targeted antineoplastic therapies

AU - Antonioli, Luca

AU - Novitskiy, Sergey V.

AU - Sachsenmeier, Kris F.

AU - Fornai, Matteo

AU - Blandizzi, Corrado

AU - Haskó, G.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Over the past few years, several preclinical studies have highlighted the value of CD73 (ecto-5′-nucleotidase) as a potential therapeutic target for cancer therapy. Indeed, the pharmacological blockade of CD73, via monoclonal antibodies or small molecules, has promise in counteracting cancer development, growth and spread. Synergistic combinations of anti-CD73 drugs with conventional cancer treatments (i.e., chemotherapy, radiation therapy, immunotherapy, targeted therapy) have increased therapeutic potential. In this review, we discuss the potential synergistic effects of CD73 blockers and conventional antineoplastic therapies in the treatment of cancer.

AB - Over the past few years, several preclinical studies have highlighted the value of CD73 (ecto-5′-nucleotidase) as a potential therapeutic target for cancer therapy. Indeed, the pharmacological blockade of CD73, via monoclonal antibodies or small molecules, has promise in counteracting cancer development, growth and spread. Synergistic combinations of anti-CD73 drugs with conventional cancer treatments (i.e., chemotherapy, radiation therapy, immunotherapy, targeted therapy) have increased therapeutic potential. In this review, we discuss the potential synergistic effects of CD73 blockers and conventional antineoplastic therapies in the treatment of cancer.

UR - http://www.scopus.com/inward/record.url?scp=85021998185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021998185&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2017.06.005

DO - 10.1016/j.drudis.2017.06.005

M3 - Review article

C2 - 28676406

AN - SCOPUS:85021998185

VL - 22

SP - 1686

EP - 1696

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 11

ER -